EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV ‐2 patients

Gaelle Baudemont iD, Coralie Tardivon iD, Guillaume Monneret iD, Martin Cour iD, Thomas Rimmelé, Lorna Garnier, Hodane Yonis, Jean-Christophe Richard iD, Remy Coudereau, Morgane Gossez iD, Florent Wallet iD, Marie-Charlotte Delignette iD und 8 weitere

CPT: Pharmacometrics & Systems Pharmacology · 2024-07 · 13 (7) · 1130-1143

DOI: 10.1002/psp4.13145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 05.06.2024. Verfasst von Gaelle Baudemont und 19 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France. Hauptthemen laut MEDLINE: COVID-19, Monocytes, HLA-DR Antigens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent SarsCov2 pandemic has disrupted healthcare system notably impacting intensive care units (ICU). In severe cases, the immune system is dysregulated, associating signs of hyperinflammation and immunosuppression. In the present work, we investigated, using a joint modeling approach, whether the trajectories of cellular immunological parameters were associated with survival of COVID‐19 ICU patients. This study is based on the REA‐IMMUNO‐COVID cohort including 538 COVID‐19 patients admitted to ICU between March 2020 and May 2022. Measurements of monocyte HLA‐DR expression (mHLA‐DR), counts of neutrophils, of total lymphocytes, and of CD4+ and CD8+ subsets were performed five times during the first month after ICU admission. Univariate joint models combining survival at day 28 (D28), hospital discharge and longitudinal analysis of those biomarkers’ kinetics with mixed‐effects models were performed prior to the building of a multivariate joint model. We showed that a higher mHLA‐DR value was associated with a lower risk of death. Predicted mHLA‐DR nadir cutoff value that maximized the Youden index was 5414 Ab/C and led to an AUC = 0.70 confidence interval (95%CI) = [0.65; 0.75] regarding association with D28 mortality while dynamic predictions using mHLA‐DR kinetics until D7, D12 and D20 showed AUCs of 0.82 [0.77; 0.87], 0.81 [0.75; 0.87] and 0.84 [0.75; 0.93]. Therefore, the final joint model provided adequate discrimination performances at D28 after collection of biomarker samples until D7, which improved as more samples were collected. After severe COVID‐19, decreased mHLA‐DR expression is associated with a greater risk of death at D28 independently of usual clinical confounders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19MonocytesHLA-DR AntigensHumansMaleFemaleMiddle AgedAgedIntensive Care UnitsSARS-CoV-2BiomarkersSeverity of Illness Index

Substanzen

HLA-DR AntigensBiomarkers

Autor:innen und Institutionen

  • Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France.
  • Département d'Epidémiologie Biostatistique et Recherche Clinique, AP-HP.Nord, Hôpital Bichat, Paris, France.
  • Centre d'Investigations Cliniques-Epidémiologie Clinique 1425, INSERM, Hôpital Bichat, Paris, France.
  • Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hôpital, Lyon, France.
  • Joint Research Unit HCL-bioMérieux, EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon - bioMérieux), Lyon, France.
  • Medical intensive Care Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

ORCID-Profile: Gaelle Baudemont, Coralie Tardivon, Guillaume Monneret, Martin Cour, Jean-Christophe Richard, Morgane Gossez, Florent Wallet, Marie-Charlotte Delignette, Marielle Buisson, Anne-Claire Lukaszewicz, Laurent Argaud, Cédric Laouenan, Julie Bertrand, Fabienne Venet

Zitieren

APA

Baudemont, G., Tardivon, C., Monneret, G., Cour, M., Rimmelé, T., Garnier, L., Yonis, H., Richard, J. C., Coudereau, R., Gossez, M., Wallet, F., Delignette, M. C., Dailler, F., Buisson, M., Lukaszewicz, A. C., Argaud, L., Laouenan, C., Bertrand, J., Venet, F., & RICO study group (2024). Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV ‐2 patients. CPT: Pharmacometrics & Systems Pharmacology, 13(7), 1130-1143. https://doi.org/10.1002/psp4.13145

Vancouver

Baudemont G, Tardivon C, Monneret G, Cour M, Rimmelé T, Garnier L, et al. Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV ‐2 patients. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(7):1130-1143. doi:10.1002/psp4.13145

BibTeX
@article{Baudemont2024,
  author = {Baudemont, Gaelle and Tardivon, Coralie and Monneret, Guillaume and Cour, Martin and Rimmelé, Thomas and Garnier, Lorna and Yonis, Hodane and Richard, Jean-Christophe and Coudereau, Remy and Gossez, Morgane and Wallet, Florent and Delignette, Marie-Charlotte and Dailler, Frederic and Buisson, Marielle and Lukaszewicz, Anne-Claire and Argaud, Laurent and Laouenan, Cédric and Bertrand, Julie and Venet, Fabienne and RICO study group, RICO study group},
  title = {Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV ‐2 patients},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  volume = {13},
  number = {7},
  pages = {1130--1143},
  doi = {10.1002/psp4.13145}
}
Kostenlos starten →